Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Garmin Ltd. (GRMN) vs Invesco Ltd. (IVZ) Price & Performance

Garmin Ltd.Trade
Invesco Ltd.Trade

Price performance (Past 24H)

Key statistics

Garmin Ltd. vs Invesco Ltd. — how do they compare? Garmin Ltd. trades at $268.36 (market cap $51.77B), while Invesco Ltd. trades at $29.51 (market cap $13.28B). The key difference: Garmin Ltd. is far larger — about 3.9× Invesco Ltd.'s market cap, and Invesco Ltd. pays the higher dividend (2.86%). Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and Invesco Ltd. for 77 Days on average.

GRMNIVZ
Market Cap
$51.77B$13.28B
Volume
961,3983,698,033
Sector
TechnologyFinancials
52-Week High
$313.16$33.31
52-Week Low
$187.10$22.44
Typical Hold Time
83 Days77 Days
Enterprise Value
$49.28B$23.45B
Dividend Yield
1.56%2.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Garmin Ltd.

Garmin (GRMN) trades at $268.36, down 2.82% on the day, reflecting a recent bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.81 surpassing the $2.30 expectation. Revenue and net income have shown steady growth, reaching $7.25 billion and $1.66 billion respectively in 2025. Positive news includes product awards and new feature rollouts, yet analyst consensus remains heavily weighted toward Hold.

The outlook balances robust profitability and growth against a cautious Wall Street sentiment and near-term technical weakness. Investment opportunity lies in the company's strong execution and product innovation, but risks include competitive pressures and market volatility. The consensus price target of $320.25 suggests significant potential upside from the current price if positive earnings trends continue.

Invesco Ltd.

Invesco (IVZ) trades at $29.51, down 3.25% today, with bearish technical signals dominating. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026, while Q3 2026 results are pending. Despite negative net income margins in 2025, operating cash flow remains strong at $1.53 billion, and analyst consensus leans toward Hold with a $33.71 price target. Recent news highlights ETF expansions and AUM growth to $2.56 trillion in August 2026.

The outlook is cautious; IVZ faces profitability challenges with negative ROE and net margins, but solid cash flow and analyst buy ratings (42.86%) suggest recovery potential. Risks include earnings volatility and competitive ETF pressures, while institutional sentiment is neutral. The stock's current price near the low end of analyst targets ($28-$41) may appeal to value investors betting on operational improvements.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Garmin Ltd.

Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.

Read more on GRMN →

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ →